ImClone Systems’ data from the Phase II OPUS study show that the addition of Erbitux to Folfox chemotherapy significantly improves both response rate and progression-free survival over Folfox alone in the first-line treatment of metastatic colorectal cancer (mCRC) patients whose tumors do not have mutations of the K-Ras oncogene (K-Ras wild-type).     The randomized first-line Phase II study of 337 patients compared Erbitux plus Folfox to Folfox alone in epidermal growth factor recepto...